Skip to main content
Premium Trial:

Request an Annual Quote

MediChem, Rigel Pen Structural Proteomics Deal

NEW YORK, Sept. 6 – MediChem and Rigel Pharmaceuticals announced a two-year structural proteomics collaboration to search for new treatments in the area of ubiquitin ligases, which are involved in cell division and the progression of some cancers.

Under the terms of the deal, MediChem's Emerald BioStructures structural proteomics unit will express, purify, and crystallize proteins that Rigel is focusing on in its oncology program. 

"Ubiquitin ligase activity has become a very important and promising area of discovery research for cancer therapeutics," Donald Payan, chief scientific officer for Rigel, said in a statement released Wednesday.

"The structural information that we gain through our collaboration with MediChem will have a significant impact on the outcome of our drug discovery programs," he added. 

Rigel will pay MediChem for research it conducts and will also provide milestone payments for completion of specified scientific achievements. Rigel will retain rights to certain technology, data, and improvements to MediChem's structural proteomics technology platform.

Rigel of South San Francisco, Calif., will also grant Chicago-based MediChem a right of discussion on all future medicinal chemistry partnering opportunities as related to the targets researched during this collaboration. 

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.